Lb Pharmaceuticals (LBRX) Interest & Investment Income (2024 - 2026)

Lb Pharmaceuticals' Interest & Investment Income history runs 3 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income rose 1107.63% year-over-year to $2.8 million in Q1 2026; TTM through Mar 2026 was $6.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $3.9 million, up 127.77% from the prior year.
• Interest & Investment Income rose to $2.8 million in Q1 2026 per LBRX's latest filing, from $2.8 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $2.8 million in Q1 2026 and bottomed at $236000.0 in Q1 2025.
• The 3-year median for Interest & Investment Income is $545500.0 (2024), against an average of $1.2 million.
• Across the five-year window, Interest & Investment Income surged 84.11% in 2025 and jumped 1107.63% in 2026, its largest moves.
• Year by year, Interest & Investment Income stood at $298000.0 in 2024, then surged by 839.6% to $2.8 million in 2025, then increased by 1.79% to $2.8 million in 2026.
• Per Business Quant, the three latest LBRX Interest & Investment Income figures stand at $2.8 million (Q1 2026), $2.8 million (Q4 2025), and $707000.0 (Q3 2025).